Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
Zhejiang DTRM Biopharma
Zhejiang DTRM Biopharma
OHSU Knight Cancer Institute
Dana-Farber Cancer Institute
Mayo Clinic
Boston Medical Center
Duke University
Technical University of Munich